Study will explore the promise of AerWave's
safer, shorter, and more efficacious lung denervation procedures
for Chronic Obstructive Pulmonary Disease and Asthma
patients
NEW
YORK, April 23, 2024 /PRNewswire/ -- Lucius
Partners, LLC ("LP") today announced that its portfolio
company, AerWave Medical, Inc., has begun screening patients
for inclusion in First in Human (FIH) studies of the Company's
unique ultrasound platform for lung denervation.
The study will evaluate patients undergoing lung denervation
utilizing AerWave's novel approach to treat asthma and chronic
obstructive pulmonary disease (COPD). The study is expected to
enroll five patients and will evaluate the safety and potential
efficacy of lung denervation with the Company's innovative, time
saving approach. The protocols are supported by extensive
pre-clinical trials and data on both the safety and efficacy
of dosimetry-based ultrasound denervation. The Company's technology
holds promise for a shorter, more efficacious, and safer clinical
lung denervation procedure.
"Our studies to date indicate that AerWave's balloon-based
ultrasound platform has the potential to reduce COPD and lung
exacerbations in asthma," said Reinhard Warnking, AerWave
Medical President and Chief Technology officer. "These
exacerbations can lead to hospitalizations and can cause
significant morbidity and mortality. While pharmaceutical options
can improve a patient's functional status, they have not yet been
shown to cure the disease. We believe safe, pathopysiological
approaches can improve both efficacy and a patient's quality of
life."
Generally, increased exacerbations are indicative of a higher
likelihood of a poor prognosis for COPD patients. There has been a
lack of new approaches to address this key unmet need. Extensive
research on the role of nerves in the respiratory system suggests
that lung denervation could offer an important option for patients
and clinicians.
"Assessing and managing COPD exacerbations is a complex process
requiring new treatments that provide a durable reduction in these
events," said Patrick Gallagher,
Director. "AerWave believes that its system, which offers
significant potential safety and procedure advantages over current
interventional treatments could meaningfully improve clinical
prognosis and reduce costs to the healthcare system."
In addition to the platform's potential safety and speed
advantages, its use of ultrasound energy affords multiple pipeline
opportunities, including tumor ablation and lung volume
reduction.
"The AerWave team continues to drive achievement of its
milestones through a deliberate process," said James Ahern, Managing Partner at Laidlaw &
Company and Founding Partner of Lucius Partners. "We believe the
FIM trial can drive meaningful value creation for the Company as
demonstration of the platform's safety and utility could ultimately
expand the treatable patient population."
About AerWave Medical, Inc.
AerWave Medical is
dedicated to creating and advancing medical devices to address
unmet medical needs in Pulmonary medicine and beyond, using
proprietary ultrasound technology developed by our highly
accomplished scientists. For more information, please visit AerWave
Medical.
About Lucius Partners, LLC
Lucius Partners is a
consultancy that provides a broad suite of services to help
healthcare companies grow, achieve milestones, and generate value
for their shareholders. Learn more about Lucius Partners here.
Contact
Patrick
Gallagher
Managing Partner, Lucius Partners, LLC
pgallagher@luciuspartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucius-partners-llc-portfolio-company-aerwave-medical-inc-initiates-patient-screening-in-preparation-for-first-in-human-studies-302124781.html
SOURCE Lucius Partners, LLC